Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm

BACKGROUND: At present, immune checkpoint inhibitors, such as pembrolizumab, are widely used in the therapy of advanced non-resectable melanoma, as they induce more durable responses than other available treatments. However, the overall response rate does not exceed 50% and, considering the high cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsur, Neta, Kogan, Yuri, Avizov-Khodak, Evgenia, Vaeth, Désirée, Vogler, Nils, Utikal, Jochen, Lotem, Michal, Agur, Zvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781362/
https://www.ncbi.nlm.nih.gov/pubmed/31590677
http://dx.doi.org/10.1186/s12967-019-2081-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781362/
https://www.ncbi.nlm.nih.gov/pubmed/31590677
http://dx.doi.org/10.1186/s12967-019-2081-2

Ejemplares similares